EUVIMEDEUVIMED entdecken
Crossref

Characteristics of Authorized Clinical Trials in Peru, 2017–2025: A National Registry-Based Study

Liz Mendoza-Aucaruri, Alexander Gabriel Acevedo-Cahuana, Fritzi Pilar Villalba-Ugarte, Luis Ttito-Paricahua, Diego André Ale-Mauricio, Alvaro Taype-Rondan

Therapeutic Innovation & Regulatory Science · 2026-11 · 60 (6) · 1916-1928

DOI: 10.1007/s43441-026-01040-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 31.08.2026. Verfasst von Liz Mendoza-Aucaruri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina Humana, Universidad Científica del Sur, Lima, Peru. Hauptthemen laut MEDLINE: COVID-19, Clinical Trials as Topic. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In Peru, the regulatory framework governing clinical research has evolved substantially, particularly during the COVID-19 pandemic; however, recent patterns of authorized clinical trials (CTs) have not been systematically described.

Objective

To characterize authorized CTs in Peru and to describe their evolution across the pre-pandemic (2017–2019), pandemic (2020–2022), and post-pandemic (2023–2025) periods.

Methods

Retrospective descriptive study using secondary data from the Peruvian Clinical Trial Registry (REPEC). All CTs authorized between January 2017 and December 2025 were included. Trial, population, geographic, and regulatory characteristics were assessed. Categorical variables were compared using chi-square or Fisher’s exact tests, and continuous variables using the Kruskal–Wallis test.

Results

A total of 421 authorized CTs were analyzed. Most were foreign-sponsored (90.0%) and conducted by private institutions (86.2%). Phase III trials (72.2%) with randomized (84.6%), double-blind (61.5%), and parallel designs (88.6%) predominated. Oncology was the most frequent therapeutic area (32.5%), while medical specialties varied across periods ( p = 0.002), with infectious-disease trials increasing during the pandemic (24.9%) and declining thereafter (9.8%). Most trials planned to enroll both sexes (91.0%) and adults (92.6%); inclusion of older adults (≥ 65 years) differed by periods ( p = 0.001). Most trials were planned to be conducted in Lima (96.4%). Median time to authorization was 75 days in 2020, peaked at 405.5 days in 2022, and declined to 127.5 days in 2025, remaining above pre-pandemic levels (90.5–109 days).

Conclusions

Authorized CTs in Peru remain predominantly foreign-sponsored, late-phase, and geographically concentrated in the capital. The COVID-19 pandemic was associated with notable shifts in trial characteristics and substantial disruption of regulatory timelines, with only partial recovery thereafter. The CT profile appeared to show limited alignment with national health priorities, highlighting the importance of orienting clinical research toward population health needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Clinical Trials as TopicPeruHumansRegistriesRetrospective StudiesFemaleSARS-CoV-2PandemicsMale

Stichwörter der Autor:innen

COVID-19Clinical trials as topicDrug approvalLatin America (MeSH terms)PeruRegistries

Autor:innen und Institutionen

  • Facultad de Medicina Humana, Universidad Científica del Sur, Lima, Peru.
  • Facultad de Medicina Humana, Universidad Nacional del Centro del Perú, Huancayo, Peru.
  • CIPHER-LAC, Collaborative Initiative for Public Health and Epidemiological Research in Latin America and the Caribbean, Universidad Científica del Sur, Lima, Peru.
  • Universidad Nacional Jorge Basadre Grohmann, Tacna, Peru.
  • Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru. alvaro.taype.r@gmail.com.

Zitieren

APA

Mendoza-Aucaruri, L., Acevedo-Cahuana, A. G., Villalba-Ugarte, F. P., Ttito-Paricahua, L., Ale-Mauricio, D. A., & Taype-Rondan, A. (2026). Characteristics of Authorized Clinical Trials in Peru, 2017–2025: A National Registry-Based Study. Therapeutic Innovation & Regulatory Science, 60(6), 1916-1928. https://doi.org/10.1007/s43441-026-01040-9

Vancouver

Mendoza-Aucaruri L, Acevedo-Cahuana AG, Villalba-Ugarte FP, Ttito-Paricahua L, Ale-Mauricio DA, Taype-Rondan A. Characteristics of Authorized Clinical Trials in Peru, 2017–2025: A National Registry-Based Study. Therapeutic Innovation & Regulatory Science. 2026;60(6):1916-1928. doi:10.1007/s43441-026-01040-9

BibTeX
@article{MendozaAucaruri2026,
  author = {Mendoza-Aucaruri, Liz and Acevedo-Cahuana, Alexander Gabriel and Villalba-Ugarte, Fritzi Pilar and Ttito-Paricahua, Luis and Ale-Mauricio, Diego André and Taype-Rondan, Alvaro},
  title = {Characteristics of Authorized Clinical Trials in Peru, 2017–2025: A National Registry-Based Study},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {6},
  pages = {1916--1928},
  doi = {10.1007/s43441-026-01040-9}
}
Kostenlos starten →